LABU:NYE-Direxion Daily S&P Biotech Bull 3X Shares (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 127.71

Change

0.00 (0.00)%

Market Cap

USD 0.91B

Volume

0.85M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

ETFs Containing LABU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8,276.49% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 8,276.49% 97% N/A 99% N/A
Trailing 12 Months  
Capital Gain 15,013.61% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 15,013.61% 97% N/A 99% N/A
Trailing 5 Years  
Capital Gain 1,201.50% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,201.50% 94% A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 367.34% 97% N/A 99% N/A
Dividend Return 367.44% 97% N/A 99% N/A
Total Return 0.10% 6% D- 4% F
Risk Return Profile  
Volatility (Standard Deviation) 2,407.64% 4% F 1% F
Risk Adjusted Return 15.26% 30% F 34% F
Market Capitalization 0.91B 84% B 56% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.